New Competitive Intelligence Report on HIV Small Molecule Therapeutics Published at

10 Jan 2012 • by Natalie Aster

LONDON – Despite a high current standard of care in antiretroviral therapy for HIV, multidrug-resistant strains continue to emerge, underscoring the need for additional novel mechanism inhibitors that will offer expanded therapeutic options in the clinic.

New research report “Competitor Analysis: HIV Small Molecule Therapeutics” worked out by La Merie Publishing has been recently published by Market Publishers Ltd.

Report Details:

Competitor Analysis: HIV Small Molecule Therapeutics
Published: December, 2011
Pages: 100
Price: US$ 642,00

The report presents a competitor evaluation in the field of marketed products and R&D projects of HIV small molecule therapeutics. It is also supplemented with a list of company-specific product portfolios and R&D pipelines of HIV small molecule therapeutics.

Competitor projects are listed in a tabular format providing information on:

  • drug codes;
  • target/mechanism of action;
  • class of compound;
  • company;
  • product category;
  • indication;
  • R&D stage;
  • additional comments with a hyperlink leading to the source of information.

More new competitive intelligence reports and other studies by the publisher can be found at La Merie Publishing page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970